To the Editor I write on behalf of my coauthors to explain several important reporting failures in our article, “Association of O⁶-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer,” that was published online on September 13, 2017, and in the November 2017 issue of JAMA Surgery.¹ This included failure to cite related articles with similar study designs that included many patients from the same overall sample. In our JAMA Surgery article, we examined O⁶-methylguanine-DNA methyltransferase protein expression as a prognostic factor among patients with gastric cancer who had undergone gastrectomy with D2 lymphadenectomy. This study was conducted at Zhongshan Hospital at Fudan University in Shanghai, China, between August 1, 2007, and December 30, 2008. We had conducted similar studies on different biomarkers in many of the same patients at this hospital.^2-10 We should have informed the editors of these related studies and should have discussed and cited these studies in our JAMA Surgery article as is required by the journal.¹¹